Anja Vaskinn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anja Vaskinn has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Ole Andreas Andreassen
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
38 shared publications Ingrid Melle
Institute of Clinical Medicine, Norwegian Centre for Mental Disorders Research, University of Oslo, Oslo, Norway
22 shared publicationsKjetil Sundet
Department of Psychology, University of Oslo, Norway
20 shared publicationsTorill Ueland
Department of Psychology, University of Oslo, Oslo, Norway
18 shared publicationsOle A. Andreassen
Centre for Precision Psychiatry, Faculty of Medicine, University of Oslo, Norway
13 shared publications- Halldóra Jónsdóttir
Division of Psychiatry, Ulleval University Hospital, Oslo, Norway
12 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Springer Nature in Review Journal of Autism and Developmental Disorders
- p. 1-7
Autism Spectrum Disorders in Imprisoned Women: A Concise Systematic Review
- 21 May 2026
- Published by Springer Nature in Review Journal of Autism and Developmental Disorders
- p. 1-7
Open AccessAutism Spectrum Disorders in Imprisoned Women: A Concise Systematic Review
- Open Access
- 23 March 2026
- Published by Elsevier in Schizophrenia Research: Cognition
- Vol. 45, 100433
Cognition at baseline and relationships 10 years after a first episode of schizophrenia
- 23 March 2026
- Published by Elsevier in Schizophrenia Research: Cognition
- Vol. 45, 100433
Open AccessCognition at baseline and relationships 10 years after a first episode of schizophrenia
- Open Access
- 2 September 2025
- Published by Walter de Gruyter GmbH in Society & Animals
- Vol. 33 (7-8) , 797-803
The Double Standards of the Association for the Treatment and Prevention of Sexual Abuse (ATSA)
The Association for the Treatment and Prevention of Sexual Abuse ( ATSA ) is an organization for researchers and clinicians in the field concerned with treatment and understanding of individuals who have committed sexual abuse or are at risk of committing sexual abuse. ATSA ’s annual conference for 2025 takes place at a SeaWorld hotel, a choice which stands in contrast to ATSA ’s mission of preventing abuse. This commentary reviews the history of animal exploitation and ongoing maltreatment that enable the continued public display of animals at oceanaria such as SeaWorld. The scientific evidence of an overlap and similarities between violence and abuse against human and nonhuman animals is summarized, highlighting how abuse of nonhuman animals is not without relevance for ATSA ’s members. Choosing a conference venue affiliated with abuse and exploitation of nonhuman animals unveils the double standards of an organization whose mission is to prevent abuse.
- 2 September 2025
- Published by Walter de Gruyter GmbH in Society & Animals
- Vol. 33 (7-8) , 797-803
Open AccessThe Double Standards of the Association for the Treatment and Prevention of Sexual Abuse (ATSA)
The Association for the Treatment and Prevention of Sexual Abuse ( ATSA ) is an organization for researchers and clinicians in the field concerned with treatment and understanding of individuals who have committed sexual abuse or are at risk of committing sexual abuse. ATSA ’s annual conference for 2025 takes place at a SeaWorld hotel, a choice which stands in contrast to ATSA ’s mission of preventing abuse. This commentary reviews the history of animal exploitation and ongoing maltreatment that enable the continued public display of animals at oceanaria such as SeaWorld. The scientific evidence of an overlap and similarities between violence and abuse against human and nonhuman animals is summarized, highlighting how abuse of nonhuman animals is not without relevance for ATSA ’s members. Choosing a conference venue affiliated with abuse and exploitation of nonhuman animals unveils the double standards of an organization whose mission is to prevent abuse.
- Open Access
- 12 February 2025
- Published by Elsevier in Schizophrenia Research: Cognition
- Vol. 40, 100350
Social cognitive training among individuals with schizophrenia: Identifying responders to treatment
- 12 February 2025
- Published by Elsevier in Schizophrenia Research: Cognition
- Vol. 40, 100350
Open AccessSocial cognitive training among individuals with schizophrenia: Identifying responders to treatment
- Open Access
- 28 December 2024
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin Open
- Vol. 6 (1) , sgae031
The startle response and prepulse inhibition in psychosis and violence: A combined electromyography and electroencephalography study
There is a pressing need for biomarkers of violent behavior risk in psychosis. Previous research indicates that electrophysiological measures of automatic defensive reactions may have potential. The purpose of this study was to investigate associations between violent behavior in individuals with and without psychosis and electromyography (EMG) and electroencephalography (EEG) responses to startling auditory stimuli. EMG and EEG was recorded during an auditory startle paradigm from healthy controls (HC, n=211), individuals with psychosis and a history of violent behavior (violent-PSY, n=18), individuals with psychosis without a history of violence (nonviolent-PSY, n=32), and individuals with a history of violence without psychosis (violent non-PSY, n=22). We estimated the auditory startle response (ASR) and prepulse inhibition (PPI) using EMG (i.e., EMGASR and EMGPPI) and the auditory evoked potential (i.e., AEPASR and AEPPPI) of the EEG. There were no significant effects of group on the EMGASR (p = 0.10) or the 30-ms, 60-ms, and 120-ms prepulse + pulse EMGPPI amplitudes (p = 0.11, p = 0.19, and p = 0.50, respectively). The N1 amplitude of the AEPASR was reduced in the violent-PSY group (p = <.001) and the nonviolent-PSY group (p = .015) compared to HC. The P2 amplitude of the AEPASR was reduced in violent-PSY relative to nonviolent-PSY (p = .003), violent non-PSY (p = .016), and HC (p < .001). Together, these results show that EEG-based neural responses to startling auditory stimuli are promising biomarkers of violence risk in psychosis.
- 28 December 2024
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin Open
- Vol. 6 (1) , sgae031
Open AccessThe startle response and prepulse inhibition in psychosis and violence: A combined electromyography and electroencephalography study
There is a pressing need for biomarkers of violent behavior risk in psychosis. Previous research indicates that electrophysiological measures of automatic defensive reactions may have potential. The purpose of this study was to investigate associations between violent behavior in individuals with and without psychosis and electromyography (EMG) and electroencephalography (EEG) responses to startling auditory stimuli. EMG and EEG was recorded during an auditory startle paradigm from healthy controls (HC, n=211), individuals with psychosis and a history of violent behavior (violent-PSY, n=18), individuals with psychosis without a history of violence (nonviolent-PSY, n=32), and individuals with a history of violence without psychosis (violent non-PSY, n=22). We estimated the auditory startle response (ASR) and prepulse inhibition (PPI) using EMG (i.e., EMGASR and EMGPPI) and the auditory evoked potential (i.e., AEPASR and AEPPPI) of the EEG. There were no significant effects of group on the EMGASR (p = 0.10) or the 30-ms, 60-ms, and 120-ms prepulse + pulse EMGPPI amplitudes (p = 0.11, p = 0.19, and p = 0.50, respectively). The N1 amplitude of the AEPASR was reduced in the violent-PSY group (p = <.001) and the nonviolent-PSY group (p = .015) compared to HC. The P2 amplitude of the AEPASR was reduced in violent-PSY relative to nonviolent-PSY (p = .003), violent non-PSY (p = .016), and HC (p < .001). Together, these results show that EEG-based neural responses to startling auditory stimuli are promising biomarkers of violence risk in psychosis.
- Open Access
- 1 September 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (12) , 3519-3529
Longitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls
Background: While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship.Methods: Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n = 221), and healthy controls (HC, n = 220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups.Results: There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course.Conclusions: Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.
- 1 September 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (12) , 3519-3529
Open AccessLongitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls
Background: While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship.Methods: Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n = 221), and healthy controls (HC, n = 220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups.Results: There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course.Conclusions: Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.
- Open Access
Longitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls
Background While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship. Methods Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n=221), and healthy controls (HC, n=220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups. Results There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course. Conclusions Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.
Open AccessLongitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls
Background While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship. Methods Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n=221), and healthy controls (HC, n=220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups. Results There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course. Conclusions Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.
- Open Access
- 20 January 2024
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 27 (5) , 661-667
Sex differences in social cognition among individuals with schizophrenia and in healthy control participants: a secondary analysis of published data
Purpose: Sex differences are present among individuals experiencing schizophrenia. Whether these differences extend to social cognition is unclear. In this study, we investigated sex differences in emotion perception, social perception and theory of mind (ToM). Methods: We examined sex differences between males and females with schizophrenia on five social cognitive tests. Healthy male and female control participants were included to examine if any sex difference was illness-specific. Emotion perception was measured with Pictures of Facial Affect (PFA) and Emotion in Biological Motion (EmoBio); social perception with the Relationships Across Domains Test (RAD); and ToM with the Movie for the Assessment of Social Cognition (MASC) and Hinting Task. Results: Two-way analyses of variance revealed overall group differences for all tests, with healthy controls outperforming individuals with schizophrenia. Significant sex effects were present for PFA and Hinting Task. There were no significant interaction effects. Within-group independent samples t-tests yielded one significant sex difference, i.e., among healthy controls for PFA. Conclusions: Females had better facial emotion perception than males. This sex difference was statistically significant among healthy controls and medium-large among individuals experiencing schizophrenia. There were no significant sex differences for other social cognitive domains. The study did not find evidence for a general female advantage in social cognition.
- 20 January 2024
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 27 (5) , 661-667
Open AccessSex differences in social cognition among individuals with schizophrenia and in healthy control participants: a secondary analysis of published data
Purpose: Sex differences are present among individuals experiencing schizophrenia. Whether these differences extend to social cognition is unclear. In this study, we investigated sex differences in emotion perception, social perception and theory of mind (ToM). Methods: We examined sex differences between males and females with schizophrenia on five social cognitive tests. Healthy male and female control participants were included to examine if any sex difference was illness-specific. Emotion perception was measured with Pictures of Facial Affect (PFA) and Emotion in Biological Motion (EmoBio); social perception with the Relationships Across Domains Test (RAD); and ToM with the Movie for the Assessment of Social Cognition (MASC) and Hinting Task. Results: Two-way analyses of variance revealed overall group differences for all tests, with healthy controls outperforming individuals with schizophrenia. Significant sex effects were present for PFA and Hinting Task. There were no significant interaction effects. Within-group independent samples t-tests yielded one significant sex difference, i.e., among healthy controls for PFA. Conclusions: Females had better facial emotion perception than males. This sex difference was statistically significant among healthy controls and medium-large among individuals experiencing schizophrenia. There were no significant sex differences for other social cognitive domains. The study did not find evidence for a general female advantage in social cognition.
- Open Access
- 18 December 2023
- Published by Springer Nature in Schizophrenia
- Vol. 9 (1) , 1-9
Intra- and inter-individual cognitive variability in schizophrenia and bipolar spectrum disorder: an investigation across multiple cognitive domains
There is substantial cognitive heterogeneity among patients with schizophrenia (SZ) and bipolar disorders (BD). More knowledge about the magnitude and clinical correlates of performance variability could improve our understanding of cognitive impairments. Using double generalized linear models (DGLMs) we investigated cognitive mean and variability differences between patients with SZ (n = 905) and BD spectrum disorders (n = 522), and healthy controls (HC,n = 1170) on twenty-two variables. The analysis revealed significant case-control differences on 90% of the variables. Compared to HC, patients showed larger intra-individual (within subject) variability across tests and larger inter-individual (between subject) variability in measures of fine-motor speed, mental processing speed, and inhibitory control (SZ and BD), and in verbal learning and memory and intellectual functioning (SZ). In SZ, we found that lager intra -and inter (on inhibitory control and speed functions) individual variability, was associated with lower functioning and more negative symptoms. Inter-individual variability on single measures of memory and intellectual function was additionally associated with disorganized and positive symptoms, and use of antidepressants. In BD, there were no within-subject associations with symptom severity. However, greater inter-individual variability (primarily on inhibitory control and speeded functions) was associated with lower functioning, more negative -and disorganized symptoms, earlier age at onset, longer duration of illness, and increased medication use. These results highlight larger individual differences in patients compared to controls on various cognitive domains. Further investigations of the causes and correlates of individual differences in cognitive function are warranted.
- 18 December 2023
- Published by Springer Nature in Schizophrenia
- Vol. 9 (1) , 1-9
Open AccessIntra- and inter-individual cognitive variability in schizophrenia and bipolar spectrum disorder: an investigation across multiple cognitive domains
There is substantial cognitive heterogeneity among patients with schizophrenia (SZ) and bipolar disorders (BD). More knowledge about the magnitude and clinical correlates of performance variability could improve our understanding of cognitive impairments. Using double generalized linear models (DGLMs) we investigated cognitive mean and variability differences between patients with SZ (n = 905) and BD spectrum disorders (n = 522), and healthy controls (HC,n = 1170) on twenty-two variables. The analysis revealed significant case-control differences on 90% of the variables. Compared to HC, patients showed larger intra-individual (within subject) variability across tests and larger inter-individual (between subject) variability in measures of fine-motor speed, mental processing speed, and inhibitory control (SZ and BD), and in verbal learning and memory and intellectual functioning (SZ). In SZ, we found that lager intra -and inter (on inhibitory control and speed functions) individual variability, was associated with lower functioning and more negative symptoms. Inter-individual variability on single measures of memory and intellectual function was additionally associated with disorganized and positive symptoms, and use of antidepressants. In BD, there were no within-subject associations with symptom severity. However, greater inter-individual variability (primarily on inhibitory control and speeded functions) was associated with lower functioning, more negative -and disorganized symptoms, earlier age at onset, longer duration of illness, and increased medication use. These results highlight larger individual differences in patients compared to controls on various cognitive domains. Further investigations of the causes and correlates of individual differences in cognitive function are warranted.